RxCell has announced a US patent for its induced pluripotent stem cells (iPSCs)-based cell therapy approach, a method of ...

RxCell Inc. is pleased to announce the issuance of U.S. Patent 11,946,069 entitled "Method for Generating Multiple Cellular ...

Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...

GC Therapeutics has entered gameplay with the mission of unlocking a new generation of cell therapies, uploading with $75 ...

CAR T-cell therapy carried a risk of second primary malignancy (SPM) that was no worse than that of other standard-of-care ...

Through TF-based cell fate programming, TFome is designed to yield first-in-class and best-in-class off-the-shelf cell therapy products up to 100 times more rapidly than conventional methods of cell ...

Just a few months after the reveal of Ori Biotech’s automated cell and gene therapy manufacturing platform IRO, the technical ...

It’s been almost a year since the Food and Drug Administration approved the first genetic treatments for sickle cell disease.

Enter MaxCyte, which has been developing and optimizing its Flow Electroporation® technology, allowing cells to move through ...

China’s National Intellectual Property Administration has issued notification to grant patent to PolTREG Chinese patent covers intrathecal ...